Explore highlights from the last congress.
Thank you for joining us at ISTH 2024 in Bangkok!
We look forward to seeing you again next year in Washington, USA, 21–25 June 2025.
In the meantime, the next opportunity to experience our coagulation portfolio and exchange with our experts will be the ADLM 2024 Clinical Lab Expo, Chicago, IL, USA, 28 July–1 August 2024.
See how data-driven blood analysis comes together so you can gain the insights to guide the many decisions that impact each individual patient.
Each patient is a unique case, and determining the source of symptoms can be anything but straightforward. Blood analysis, spanning hemostasis, hematology, and related fields, serves as a vital component to investigate every suspicion that presents along the pathway, including screening, diagnostic exclusion, and treatment monitoring. Siemens Healthineers has long understood this paradigm and remains committed to delivering innovation in hemostasis and hematology diagnostics and beyond.
Explore a comprehensive range of integrated blood testing solutions, from advanced optical methodologies and routine platelet aggregation testing to full-field imaging powered by artificial intelligence, enabling you to dig deeper into disease states. Learn how our portfolio helps you advance diagnostics.
CN-3000 and CN-6000 Systems1 are mid- and high-volume coagulation systems that combine fast, smart, and flexible testing in a small footprint.
INNOVANCE® PFA-200 System1 is a platelet function analyzer for automated assessment for inherited, acquired, or drug-induced platlet dysfunction.
Atellica® HEMA 570 and 580 Analyzers1 are scalable, easy-to-use hematology analyzers that can seamlessly integrate into your lab's high-volume workflow.
Scopio X100 and X100HT imaging platforms are the world’s first full-field digital cell morphology solutions, complete with AI-powered decision support.
Our scalable, configurable portfolio of automated lab and IT solutions enhance workflows in any-sized lab. Discover the possibilities.
Data is a key to accuracy, offering clinicians clarity when confronted with ambiguity. Data is a key to efficiency, enabling labs to do more, without more and data is a key to accessibility, breaking down barriers that prevent populations from receiving high-quality healthcare. Experience how Atellica® Diagnostics IT simplifies data management and consolidates information from diverse sources to draw a holistic clinical picture.
Just as every patient story is unique, so is your lab. Our scalable, configurable portfolio of automated lab solutions supports varying needs, spaces, and discipline-specific requirements to enhance workflows in any-sized lab. Explore flexible options and innovative approaches to increase workflow efficiency with Aptio® Automation.
Our broad portfolio of routine and specialty hemostasis assays supports physicians in making sound diagnostic and therapeutic decisions. To help you simplify tasks and improve workflows, we continuously expand our portfolio with new technologies and ready-to-use solutions. Learn how to enhance cinical insights in bleeding management.
Improve bleeding patient management
While the majority of von Willebrand disease (VWD) patients suffer from a congenital, lifelong bleeding disorder, certain chronic diseases and therapies can lead to acquired VWD. Check out our resources for recent testing guidelines and advancements in VWD diagnostics.
Explore our unparalleled bleeding portfolio
Streamline diagnostic testing around primary and secondary hemostasis with tests for acquired and congenital bleeding risk assessment, from one provider.
Now available in the U.S.: INNOVANCE VWF Ac and vWF Ag assays
Take VWF diagnostics to the next level with a highly innovative, sensitive, and precise initial von Willebrand disease testing panel.
INNOVANCE PFA-2001 System
A platelet function analyzer for automated assessment of inherited, acquired, or drug-induced platelet dysfunction.
Integrated platelet aggregation testing1
An innovation that makes aggregation testing more manageable, reliable, and standardized.
Bleeding portfolio overview
A comprehensive bleeding risk assessment portfolio of systems and assays.
INNOVANCE Anti-Xa assay1 is an automated chromogenic assay for the quantitative determination of the activity of unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) as well as rivaroxaban, apixaban, and edoxaban concentrations in citrated human plasma. Download the poster to learn about its performance on coagulation analyzers from Siemens Healthineers.
Abstract: INNOVANCE® Anti-Xa assay1 in combination with drug-specific standards and controls is used for the quantitative determination of heparins (UFH, LMWH), rivaroxaban, and apixaban in human citrated plasma. Respective applications for CS-2500, CS-5100, and CN-3000/CN-6000 Systems1 are based on a chromogenic assay principle. New applications for the quantitative determination of edoxaban employing edoxaban-containing standards and controls are available now for these analyzers. The studies aimed to assess the performance of these new applications.
INNOVANCE Anti-Xa assay1
An assay that simplifies anticoagulant testing, with a combined solution for heparin and DOAC testing. Test for UFH, LMW, apixaban, rivaroxaban, and edoxaban with just one assay.
Siemens Healthineers provides flexible, expansive portfolio solutions across the core lab, including hemostasis, clinical chemistry, immunoassay, hematology, urinalysis, automation, and IT solutions, combined with vast experience and service excellence, to meet the needs of labs in all segments.
Our 40+ years of leadership in hemostasis testing is built on a strong scientific legacy of innovation in reagent development. Our hemostasis testing portfolio comprises >60 assays, including trusted, ready-to-use, highly precise INNOVANCE assays, as well as a scalable selection of coagulation analyzers from Siemens Healthineers. Whether you require a stand-alone hemostasis solution, automated hemostasis testing, or hemostasis testing combined with specific or multidisciplinary testing enhanced by digitalization, we can provide it all.
We look forward to meeting you in Washington at ISTH 2025!
Share
Do you find this page interesting? Share it with your peers.
The products/features/applications mentioned here are not commercially available in all countries and are subject to local regulations. Their future availability cannot be guaranteed. Not available for sale in the U.S.